Danmark - dansk - SEGES Landbrug & Fødevarer

bayer a/s - diflufenican, mefenpyr-diethyl, mefenpyr, iodosulfuron-methyl-na, iodosulfuron, mesosulfuron-methyl, mesosulfuron - od-formulering - 50 g/l diflufenican ; 22,5 g/l mefenpyr-diethyl ; (~ 19,1 g/l mefenpyr) ; 2,5 g/l iodosulfuron-methyl-na ; (~ 2,33 g/l iodosulfuron) ; 7,5 g/l mesosulfuron-methyl ; (~ 7,29 g/l mesosulfuron)

Danmark - dansk - SEGES Landbrug & Fødevarer

hoechst schering agrevo as - fenoxaprop-p-ethyl, phenoxaprop-p, mefenpyr-diethyl, mefenpyr - vandopløseligt koncentrat - 69 g/l fenoxaprop-p-ethyl ; (~ 63,6 g/l fenoxaprop-p ; 75 g/l mefenpyr-diethyl ; (~ 63,7 g/l mefenpyr

Danmark - dansk - SEGES Landbrug & Fødevarer

bayer a/s - fenoxaprop-p-ethyl, phenoxaprop-p, mefenpyr-diethyl, mefenpyr - olie i vand emulsion - 69 g/l fenoxaprop-p-ethyl ; (~ 63,6 g/l fenoxaprop-p) ; 75 g/l mefenpyr-diethyl ; (~ 63,7 g/l mefenpyr)

Danmark - dansk - SEGES Landbrug & Fødevarer

aventis cropscience nordic a/s - fenoxaprop-p-ethyl, phenoxaprop-p, mefenpyr-diethyl, mefenpyr - vandopløseligt koncentrat - 69 g/l fenoxaprop-p-ethyl ; (~ 63,6 g/l fenoxaprop-p ; 18 g/l mefenpyr-diethyl ; (~ 15,3 g/l mefenpyr

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

life medical aps - dienogest, ethinylestradiol - filmovertrukne tabletter - 2+0,03 mg

Den europeiske union - dansk - EMA (European Medicines Agency)

sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningitis, meningokok - vacciner - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. the use of this vaccine should be in accordance with available official recommendations.

Den europeiske union - dansk - EMA (European Medicines Agency)

eisai gmbh - rufinamide - epilepsi - antiepileptika, - inovelon er indiceret som adjuverende terapi til behandling af anfald forbundet med lennox gastaut syndrom hos patienter på 4 år og ældre.

Den europeiske union - dansk - EMA (European Medicines Agency)

astrazeneca ab - saxagliptin - diabetes mellitus, type 2 - narkotika anvendt i diabetes - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Den europeiske union - dansk - EMA (European Medicines Agency)

novartis europharm limited - dabrafenib mesilate - melanom - antineoplastiske midler - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. adjuverende behandling af melanomadabrafenib i kombination med trametinib er angivet for den adjuverende behandling af voksne patienter med stadium iii melanom med en braf v600 mutation, efter komplet resektion. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.

Den europeiske union - dansk - EMA (European Medicines Agency)

guidehouse germany gmbh - sotagliflozin - diabetes mellitus (sukkersyge), type 1 - narkotika anvendt i diabetes - zynquista er indiceret som et supplement til insulin terapi til at forbedre glykæmisk kontrol hos voksne med type 1 diabetes mellitus med et body mass index (bmi) ≥ 27 kg/m2, som ikke har opnået tilstrækkelig glykæmisk kontrol på trods af den optimale insulin terapi.